Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
39 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Prosthetic joint infections - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prosthetic joint infections - Pipeline Review, H2 2016, provides an overview of the Prosthetic joint infections (Musculoskeletal Disorders) pipeline landscape. Prosthetic joint infection (PJI) is one of the most serious complications of prosthetic joint implantation. Symptoms include pain or stiffness in joints, swelling, redness around the wound, fatigue and fever. Risk factors include age, prior arthroplasty, poor nutritional status, obesity, diabetes mellitus and advanced HIV disease.�Treatment includes antimicrobial therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prosthetic joint infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Prosthetic joint infections (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Prosthetic joint infections (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prosthetic joint infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical, Discovery and Unknown stages are 1, 2, 2 and 1 respectively. Prosthetic joint infections (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Prosthetic joint infections (Musculoskeletal Disorders). - The pipeline guide reviews pipeline therapeutics for Prosthetic joint infections (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Prosthetic joint infections (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Prosthetic joint infections (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Prosthetic joint infections (Musculoskeletal Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Prosthetic joint infections (Musculoskeletal Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Prosthetic joint infections (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Prosthetic joint infections Overview 6 Therapeutics Development 7 Pipeline Products for Prosthetic joint infections - Overview 7 Prosthetic joint infections - Therapeutics under Development by Companies 8 Prosthetic joint infections - Pipeline Products Glance 9 Late Stage Products 9 Early Stage Products 10 Unknown Stage Products 11 Prosthetic joint infections - Products under Development by Companies 12 Prosthetic joint infections - Companies Involved in Therapeutics Development 13 Cempra Inc 13 Motif Bio Plc 14 Nabriva Therapeutics AG 15 Telephus Medical LLC 16 Prosthetic joint infections - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 EPP-001 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 fusidic acid - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 lefamulin acetate - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 MTF-101 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 TNP-2092 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 TPH-101 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Prosthetic joint infections - Dormant Projects 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39
List of Tables
Number of Products under Development for Prosthetic joint infections, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Early Stage Development, H2 2016 10 Comparative Analysis by Unknown Stage Development, H2 2016 11 Products under Development by Companies, H2 2016 12 Prosthetic joint infections - Pipeline by Cempra Inc, H2 2016 13 Prosthetic joint infections - Pipeline by Motif Bio Plc, H2 2016 14 Prosthetic joint infections - Pipeline by Nabriva Therapeutics AG, H2 2016 15 Prosthetic joint infections - Pipeline by Telephus Medical LLC, H2 2016 16 Assessment by Monotherapy Products, H2 2016 17 Number of Products by Stage and Target, H2 2016 19 Number of Products by Stage and Mechanism of Action, H2 2016 21 Number of Products by Stage and Route of Administration, H2 2016 23 Number of Products by Stage and Molecule Type, H2 2016 25 Prosthetic joint infections - Dormant Projects, H2 2016 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.